Anxiolytic Peptide
Selank is a neuropeptide that reduces anxiety, sharpens focus, and improves sleep quality without the sedation, dependency, or cognitive dulling of conventional anxiolytics. It elevates BDNF, the brain's key driver of memory and neuroplasticity, while balancing stress hormones at their source.
Product
Research shows
Practical product identifiers and format details for professional review.
Content
15 mg
Format
Injectable
Composition
5 mg/ml per ml
Selank modulates the GABAergic system by increasing GABA-A receptor sensitivity and expression, producing calming effects comparable to low-dose benzodiazepines without receptor downregulation or dependence risk. It significantly elevates BDNF (brain-derived neurotrophic factor): a key driver of neuroplasticity, memory consolidation, and neuronal survival. Selank also normalises serotonin and dopamine turnover, reduces cortisol and ACTH stress hormone levels, and supports the immune system via modulation of interleukin-6 and other cytokines. The combined effect is improved sleep architecture, reduced anxiety, and enhanced cognitive performance under conditions of mental load.
Based on published research and preclinical data. All benefits are documented under research-grade conditions.
Selank produces anxiety reduction comparable to low-dose benzodiazepines by enhancing GABAergic signalling, but without receptor downregulation, tolerance development, or physical dependence. This makes it suitable for sustained use in stress-reduction protocols.
One of Selank's most documented mechanisms is its significant elevation of BDNF (brain-derived neurotrophic factor), the primary driver of synaptic plasticity, memory consolidation, and neuronal survival. Higher BDNF correlates with improved learning, recall, and long-term cognitive resilience.
By normalising serotonin and dopamine metabolism and reducing cortisol and ACTH, Selank improves sleep onset, slow-wave sleep depth, and REM quality. Users report more restorative sleep with vivid dreaming and improved morning cognition.
Selank improves attention, working memory, and cognitive performance specifically under conditions of mental load and stress: a profile distinct from sedative anxiolytics which impair cognition. It is studied as a cognitive enhancer for high-performance and academic contexts.
Selank modulates cytokine production, reducing IL-6 and other pro-inflammatory signalling molecules. This immune-regulating property supports both systemic resilience and the neuro-immune interface relevant to anxiety and mood disorders.
By balancing monoamine neurotransmitter turnover (particularly serotonin and dopamine) Selank produces stable, sustained mood improvement without the emotional blunting seen with SSRIs or the rebound seen with stimulants.
Explore selected publications on Selank, with links to the original sources.
5 publications from the research library.
Evidence type
Publication and key finding
Source
Evidence type
Preclinical study
Direct or closely related Selank evidence
Publication and key finding
Thus, we hypothesized and showed that one of Selank anti-anxiety molecular mechanisms can be associated with subtype selective concentration - dependent allosteric modulation of GABA receptors.
Protein and peptide letters
Evidence type
Preclinical study
Direct or closely related Selank evidence
Publication and key finding
Clinical studies have shown the similarity of the spectrum of physiological effects of Selank and classical benzodiazepines, such as diazepam and phenazepam.
Frontiers in pharmacology
Evidence type
Preclinical study
Direct or closely related Selank evidence
Publication and key finding
Activity of a peptide tuftsin analogue Selank was studied in outbred rats using the naloxone-precipitated morphine withdrawal model.
Bulletin of experimental biology and medicine
Evidence type
Preclinical study
Direct or closely related Selank evidence
Publication and key finding
It was shown that the anxiolytic effect of Selank is comparable to that of classical benzodiazepine drugs and that the basis of their mechanism of action may be similar.
Behavioural neurology
Evidence type
Preclinical study
Direct or closely related Selank evidence
Publication and key finding
This publication examines intranasal administration of the peptide selank regulates bdnf expression in the rat hippocampus in vivo.
Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections
Combinations used in research protocols where Selank complements other compounds.
Selank + DSIP
The complete sleep stack: Selank normalises the stress axis and promotes calm onset while DSIP drives deep slow-wave sleep architecture for maximum restoration.
View NK PeptideSelank + AC-Semax
Cognitive balance protocol: AC-Semax elevates focus and BDNF acutely while Selank provides anxiolytic grounding, preventing the edge or overstimulation some users experience with Semax alone.
View AC-Selank + AC-Semax SprayLabbieux pens are designed for 30 to 31 administrations of 10 clicks. With daily use, this corresponds to approximately one month. We recommend starting with 5 clicks and building up to 10 clicks per administration. More sensitive people may use fewer clicks.
Before using our pens, consult the manual.
Selank has been approved as an anxiolytic drug in Russia and has an established clinical safety record. The most commonly reported effects are mild fatigue or transient sedation in some individuals, particularly at higher doses. Some users report a brief 'fogginess' in the first few days of use that typically resolves. Mild nasal irritation is occasionally noted with intranasal administration. Selank does not cause respiratory depression, dependency, withdrawal syndromes, or the cognitive dulling associated with benzodiazepines. It is not known to interact with common medications, though caution is advised if combining with other GABAergic substances. Cycling is recommended to preserve efficacy.
Other products from the same range
